Compare Amphastar Pharmaceuticals Inc (AMPH) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Solaredge Technologies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Solaredge Technologies Inc trades at $33.5 (market cap $1.98B). The key difference: Solaredge Technologies Inc is far larger — about 2.3× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | SEDG | |
|---|---|---|
Market Cap | $863.95M | $1.98B |
Sector | Health | Technology |
52-Week High | $30.81 | $78.51 |
52-Week Low | $16.87 | $25.10 |
Enterprise Value | $1.26B | $1.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
SolarEdge Technologies (SEDG) trades at $31.76, down 2.79% amid weak Q3 2026 revenue guidance overshadowing a Q2 earnings beat. The stock exhibits a bearish technical trend with key support at $30 and resistance at $34. Fundamentally, the company reported a net loss of $405.45 million in 2025, though revenue grew to $1.18 billion, with profitability metrics like ROE at -58.42% reflecting ongoing challenges in the residential solar market.
The outlook remains cautious due to persistent losses and competitive pressures, but analyst consensus suggests a potential upside to $35.15. Key risks include soft U.S. demand and execution hurdles, while institutional sentiment is mixed with 20.83% buy ratings. Investors should weigh cost-control progress against macroeconomic headwinds in the solar sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
